A stepwise tool to support your review of SUSAR cases and reach compliant causality and reporting decisions
Reporting Timeline
Regulatory Requirement: SUSARs must be reported within 15 calendar days of sponsor awareness.
Date of Sponsor Awareness:
Reporting Deadline:
Days Remaining:
Progress0%
Welcome to the SUSAR Assessment Tool
How to use this tool: This stepwise tool guides you through the review of a SUSAR case. Follow the instructions at each step to reach a compliant causality and reporting decision. Your progress will be saved as you proceed.
Date when the sponsor first became aware of the case (required for reporting timeline)
Definition: A SUSAR (Suspected Unexpected Serious Adverse Reaction) is a serious adverse event that is both unexpected and believed to be caused by the investigational product.
Reporting Timeline: SUSARs must be reported to regulatory authorities within 15 calendar days of sponsor awareness.
Step 1: Serious and Unexpected?
How to assess: Determine if the event meets regulatory seriousness criteria (death, life-threatening, hospitalization, etc.) AND if it is unexpected compared to product information.
FDA IND Rule §312.32(a): An event is unexpected if its nature, severity, or frequency is not consistent with the investigator brochure or relevant documents.
Step 2: Sponsor's Causality Assessment
How to assess: Consider only case elements you can support. Is there solid evidence the investigational drug could be responsible? Do not rely solely on the investigator's opinion.
FDA requirement: The sponsor must use the "reasonable possibility" standard (not "cannot rule out"). Evidence is necessary!
Step 3: Evidence to Support Causality
How to complete: Select all evidence types present in the case. This step helps document rationale for your causality assessment.
Step 4: Anticipated by Disease or Population?
How to assess: Determine if this event commonly occurs, regardless of study drug (e.g., disease complication, endpoint, comorbidity).
Regulatory guidance: Anticipated serious adverse events common to the indication or population are "uninformative" for IND safety reports.
Step 5: Confounding Factors Present?
How to assess: Select factors present that could explain the event. Consider medical history, other drugs, or recent procedures.
Step 6: Company Clinical Comment (CCC)
How to complete: In 4-5 sentences, summarize expectedness and causality. Reference evidence and confounders; do not restate the full case narrative.
Step 7: AOSE (Analysis of Similar Events) Comment
How to complete: Review previous similar cases (by preferred term and product). Distill trend, frequencies, and outcome to help regulatory authorities assess risk context.
Assessment Result
This case does not meet seriousness/unexpectedness criteria and is NOT a SUSAR.
No expedited IND reporting required. Consider whether the event should be documented in the study files.
Assessment Result
This event relates to underlying disease or is common in the study population.
Considered "uninformative" for FDA IND safety reporting requirements. Individual reporting is NOT WARRANTED.
Case Assessment Summary
Reporting Requirements
This case has been assessed as a SUSAR and must be reported within 15 calendar days.
Date of Sponsor Awareness:
Reporting Deadline:
Days Remaining:
Next Steps:
Prepare expedited safety report for regulatory submission